Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Fong

Showing results (11-20 of 198) with videos related to

Pageof 20
Sort By:
Immunity|December 15, 2021
Cytotoxic CD4<sup>+</sup> T cells in cancer: Expanding the immune effector toolboxDavid Y Oh, Lawrence Fong
Seminars in Oncology|October 23, 2003
Immunotherapy for prostate cancerLawrence Fong, Eric J Small
Clinical Immunology (Orlando, Fla.)|February 14, 2003
Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patientsEdgar G Engleman, Lawrence Fong
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2022
Agonizing over the Stimulatory Immune Checkpoint ICOSJerry C Lee, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatmentLawrence Fong, Eric J Small
Frontiers in Oncology|January 17, 2014
Effects of RANKL-Targeted Therapy in Immunity and CancerMichael L Cheng, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Developing immunotherapy as legitimate therapy for patients with prostate cancerEric J Small, Lawrence Fong
Current Urology Reports|April 25, 2006
Immunotherapy for prostate cancerLawrence Fong, Eric J Small
Urologic Oncology|February 6, 2014
Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumorDavid Y Lou, Lawrence Fong
Current Treatment Options in Oncology|January 10, 2014
Beyond sipuleucel-T: immune approaches to treating prostate cancerMichael L Cheng, Lawrence Fong
Pageof 20

Showing results (11-20 of 198) with videos related to

Sort By:
Pageof 20
Immunity|December 15, 2021
Cytotoxic CD4<sup>+</sup> T cells in cancer: Expanding the immune effector toolboxDavid Y Oh, Lawrence Fong
Seminars in Oncology|October 23, 2003
Immunotherapy for prostate cancerLawrence Fong, Eric J Small
Clinical Immunology (Orlando, Fla.)|February 14, 2003
Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patientsEdgar G Engleman, Lawrence Fong
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2022
Agonizing over the Stimulatory Immune Checkpoint ICOSJerry C Lee, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatmentLawrence Fong, Eric J Small
Frontiers in Oncology|January 17, 2014
Effects of RANKL-Targeted Therapy in Immunity and CancerMichael L Cheng, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Developing immunotherapy as legitimate therapy for patients with prostate cancerEric J Small, Lawrence Fong
Current Urology Reports|April 25, 2006
Immunotherapy for prostate cancerLawrence Fong, Eric J Small
Urologic Oncology|February 6, 2014
Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumorDavid Y Lou, Lawrence Fong
Current Treatment Options in Oncology|January 10, 2014
Beyond sipuleucel-T: immune approaches to treating prostate cancerMichael L Cheng, Lawrence Fong
Pageof 20